Minimal change disease associated with newly diagnosed mantle cell lymphoma

• Published in: Renal failure Vol. 36; no. 4; pp. 634 - 637
• Main Authors: Khow, Kareeann S. F., Yong, Angelina S. M., Yong, Tuck Y., Kuss, Bryone J., Barbara, Jeffrey A. J., Li, Jordan Y. Z.
• Format: Journal Article
• Language: English
• Published: England Informa Healthcare USA, Inc 01.05.2014
• Subjects: Antimetabolites, Antineoplastic - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cyclophosphamide - therapeutic use; Doxorubicin - therapeutic use; Female; Glucocorticoids - therapeutic use; Humans; Lymphoma, Mantle-Cell - complications; Lymphoma, Mantle-Cell - diagnosis; Lymphoma, Mantle-Cell - drug therapy; Methotrexate - therapeutic use; Middle Aged; Nephrosis, Lipoid - complications; Nephrotic Syndrome - drug therapy; Nephrotic Syndrome - etiology; Prednisolone - therapeutic use; Prednisone - therapeutic use; Vincristine - therapeutic use
• ISSN: 0886-022X; 1525-6049
• DOI: 10.3109/0886022X.2014.883905

Abstract Mantle cell lymphoma (MCL) is a rare but aggressive form of non-Hodgkin's lymphoma. Involvement of the kidney is an infrequent occurrence in patients with MCL and can be the result of direct infiltration or paraneoplastic glomerulopathy. Proliferative glomerulonephritis, membranoproliferative glomerulonephritis and focal segmental glomerulosclerosis have previously been reported in association with MCL. We report a 55-year-old woman who developed nephrotic syndrome due to biopsy proven minimal change disease (MCD) in association with MCL. Proteinuria decreased with prednisolone treatment and MCD remains in remission without any immunosuppressant after the treatment of the underlying MCL.